These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 22870123)
1. Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy. Chiba I; Ogawa K; Morioka T; Shimoji H; Sunagawa N; Iraha S; Nishimaki T; Yoshimi N; Murayama S Oncol Lett; 2011 Jan; 2(1):21-28. PubMed ID: 22870123 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy. Ogawa K; Chiba I; Morioka T; Shimoji H; Tamaki W; Takamatsu R; Nishimaki T; Yoshimi N; Murayama S Anticancer Res; 2011 Jun; 31(6):2351-9. PubMed ID: 21737664 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma. Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559 [TBL] [Abstract][Full Text] [Related]
4. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer]. Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788 [TBL] [Abstract][Full Text] [Related]
5. High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study. Hurmuzlu M; Øvrebø K; Monge OR; Smaaland R; Wentzel-Larsen T; Viste A World J Surg Oncol; 2010 Jun; 8():46. PubMed ID: 20515502 [TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiotherapy for esophageal cancer with malignant fistula. Koike R; Nishimura Y; Nakamatsu K; Kanamori S; Shibata T Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1418-22. PubMed ID: 18234437 [TBL] [Abstract][Full Text] [Related]
7. High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome. Hurmuzlu M; Monge OR; Smaaland R; Viste A Dis Esophagus; 2010 Apr; 23(3):244-52. PubMed ID: 19664075 [TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687 [TBL] [Abstract][Full Text] [Related]
11. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544 [TBL] [Abstract][Full Text] [Related]
12. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma. Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309 [TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411 [TBL] [Abstract][Full Text] [Related]
14. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Lee JL; Park SI; Kim SB; Jung HY; Lee GH; Kim JH; Song HY; Cho KJ; Kim WK; Lee JS; Kim SH; Min YI Ann Oncol; 2004 Jun; 15(6):947-54. PubMed ID: 15151953 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Chen M; Shen M; Lin Y; Liu P; Liu X; Li X; Li A; Yang R; Ni W; Zhou X; Zhang L; Xu B; Lin J; Chen J; Tian Y Radiat Oncol; 2018 Aug; 13(1):150. PubMed ID: 30111361 [TBL] [Abstract][Full Text] [Related]
16. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Singh AK; Lockett MA; Bradley JD Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046 [TBL] [Abstract][Full Text] [Related]
17. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097 [TBL] [Abstract][Full Text] [Related]
18. Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Kato K; Ito Y; Nozaki I; Daiko H; Kojima T; Yano M; Ueno M; Nakagawa S; Takagi M; Tsunoda S; Abe T; Nakamura T; Okada M; Toh Y; Shibuya Y; Yamamoto S; Katayama H; Nakamura K; Kitagawa Y; Gastroenterology; 2021 Dec; 161(6):1878-1886.e2. PubMed ID: 34389340 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy. Zhang HQ; Wang RB; Yan HJ; Zhao W; Zhu KL; Jiang SM; Hu XG; Yu JM Asian Pac J Cancer Prev; 2012; 13(1):199-203. PubMed ID: 22502668 [TBL] [Abstract][Full Text] [Related]
20. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma. Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]